^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    NRG1 (Neuregulin 1)

    i
    Other names: NRG1, GGF, HGL, HRG, NDF, NRG1-IT2, Neuregulin 1, Heregulin
    3d
    Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations (clinicaltrials.gov)
    P3, N=94, Recruiting, SWOG Cancer Research Network | Not yet recruiting --> Recruiting
    Enrollment open
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • TMB (Tumor Mutational Burden) • NRAS (Neuroblastoma RAS viral oncogene homolog) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • MSI (Microsatellite instability) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NRG1 (Neuregulin 1)
    |
    BRAF V600E • MSI-H/dMMR • PALB2 mutation • KRAS wild-type • BRAF wild-type • RAS wild-type • ROS1 fusion • NRG1 fusion
    |
    gemcitabine • Vectibix (panitumumab) • albumin-bound paclitaxel • leucovorin calcium • Onivyde (nanoliposomal irinotecan) • fluorouracil topical
    10d
    Influence of syringic acid on schizophrenia in mice: Modulation of PI3K/AKT1/GSK3β signaling pathway, galectin-3 and MBP. (PubMed, Int Immunopharmacol)
    Moreover, SA relieved histopathological alterations in the brain induced by CPZ. The above findings suggest that SA could ameliorate CPZ-induced psychotic symptoms in mice via suppressing neuroinflammation and promoting myelin integrity, perhaps providing further benefits to people suffering from schizophrenia.
    Preclinical • Journal
    |
    NRG1 (Neuregulin 1) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • TNFA (Tumor Necrosis Factor-Alpha) • GSK3B (Glycogen Synthase Kinase 3 Beta) • GFAP (Glial Fibrillary Acidic Protein)
    12d
    Galectin-3 binds to the RGD-binding site in a glycan-independent manner and to the allosteric site and activates integrins αvβ3, αIIbβ3, and α5β1. (PubMed, bioRxiv)
    RGDfV or eptifibatide inhibited Gal3 binding to αvβ3 and αIIbβ3, respectively, but lactose, pan-galectin inhibitor, did not inhibit Gal3 binding to integrins...Known anti-inflammatory agents, Ivermectin, NRG1, and FGF1 inhibited integrin activation induced by Gal3 in αvβ3 and αIIbβ3. These findings suggest that Gal3 binding to site 2 may be a potential mechanism of pro-inflammatory and pro-thrombotic action of Gal3.
    Journal
    |
    NRG1 (Neuregulin 1) • IL6 (Interleukin 6) • LGALS3 (Galectin 3)
    13d
    Identifying regulatory driver motifs in non-small cell lung carcinoma via a systematic approach. (PubMed, PLoS One)
    Our data indicated that NRG1-SMAD4-miR-5010-5p was the most prominent sub-network motif engaged in NSCLC patients based on the degree of centrality. In vitro mechanistic studies will provide better understanding on the role of NRG1-SMAD4-miR-5010-5p motif in NSCLC cases.
    Clinical • Journal
    |
    NRG1 (Neuregulin 1) • SMAD4 (SMAD family member 4)
    14d
    Cardiovascular signaling proteins as predictors of the cardiac effects of doxorubicin treatment in children with acute lymphoblastic leukemia. (PubMed, Cardiooncology)
    Decreased concentrations CT-1 and NRG-1 during doxorubicin treatment may increase cardiomyocyte death. Changes in IL-6 and VEGF suggest doxorubicin-related inflammation and angiogenesis. These markers may help identify children at greatest risk of long-term adverse outcomes.
    Journal
    |
    NRG1 (Neuregulin 1) • IL6 (Interleukin 6) • CRP (C-reactive protein) • NPPB (Natriuretic Peptide B)
    |
    doxorubicin hydrochloride
    19d
    Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P2, N=7, Completed, Mayo Clinic | Active, not recruiting --> Completed | Trial completion date: Oct 2027 --> Apr 2025 | Trial primary completion date: Oct 2027 --> Apr 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    NRG1 (Neuregulin 1)
    |
    Herceptin (trastuzumab) • Perjeta (pertuzumab) • Xtandi (enzalutamide) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)
    20d
    Exercise training decreases Neuregulin-1 concentrations in HER2-positive breast cancer patients undergoing adjuvant trastuzumab: the CARDAPAC study. (PubMed, Breast Cancer Res Treat)
    A 12-week interval training program significantly decreased NRG1 concentration in HER2-positive patients with breast cancer treated with adjuvant trastuzumab therapy, despite the trained group presenting higher baseline NRG1 values compared to the control group. In addition, this change was neither associated with V̇O2 max nor with LVEF.
    Clinical • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • NRG1 (Neuregulin 1)
    |
    HER-2 positive
    |
    Herceptin (trastuzumab)
    24d
    A Real-World Study of Precision Treatment for Advanced Cholangiocarcinoma Based on Molecular Subtyping (ChiCTR2500111407)
    P=N/A, N=55, Not yet recruiting, Fuzhou University Affiliated Provincial Hospital; Fuzhou University Affiliated Provincial Hospital
    New trial
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • MET (MET proto-oncogene, receptor tyrosine kinase) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • MSI (Microsatellite instability) • RET (Ret Proto-Oncogene) • FGFR2 (Fibroblast growth factor receptor 2) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • NRG1 (Neuregulin 1) • VEGFA (Vascular endothelial growth factor A) • RNF43 (Ring Finger Protein 43) • TYK2 (Tyrosine Kinase 2) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    BRAF V600E • KRAS mutation • EGFR mutation • MSI-H/dMMR • HER-2 overexpression • HER-2 amplification • PIK3CA mutation • BRAF V600 • MET amplification • RET fusion • FGFR2 mutation • PALB2 mutation • FGFR2 fusion • MET mutation • IDH mutation + BRAF V600E • IDH mutation + NTRK fusion
    27d
    RXR Agonist V-125 Induces Distinct Transcriptional and Immunomodulatory Programs in Mammary Tumors of MMTV-Neu Mice Compared to Bexarotene. (PubMed, Biomedicines)
    V-125 but not bexarotene reprograms tumor transcriptional programs and the immune landscape in an anti-tumor manner in the MMTV-neu mouse model and in in vitro models of HER2+ breast cancer. This highlights its promise as a selective RXR agonist with anti-tumor and immunomodulatory activity in HER2+ breast cancer.
    Preclinical • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • NRG1 (Neuregulin 1) • CD8 (cluster of differentiation 8) • CHI3L1 (Chitinase 3-like 1) • MRC1 (Mannose Receptor C-Type 1)
    |
    Targretin oral (bexarotene oral)
    29d
    NRG1 fusions：the potential targeted treatment in non-small cell lung cancer(NSCLC). (PubMed, Crit Rev Oncol Hematol)
    Critical challenges persist, such as intrinsic resistance mediated by the heterogeneity of NRG1 fusion isoforms and compensatory activation of the epidermal growth factor receptor (EGFR) pathway. This comprehensive analysis underscores the unmet need for novel therapeutics and provides a framework for optimizing precision oncology strategies in this molecularly defined NSCLC subset, highlighting the necessity for standardized diagnostic protocols and globally collaborative clinical trials.
    Review • Journal
    |
    ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • NRG1 (Neuregulin 1)
    |
    NRG1 fusion
    1m
    The multi-omics and Mendelian randomization analyses unveiled potential marker genes in the progression of glioblastoma. (PubMed, Medicine (Baltimore))
    Moreover, Kyoto encyclopedia of genes and genomes pathways, such as Calcium signaling, MAPK signaling, cAMP signaling, and Rap1 signaling, were significantly enriched. In conclusion, our model, based on AS genes, effectively predicts glioma prognosis, identifying NRG1 as a significant marker.
    Journal
    |
    NRG1 (Neuregulin 1) • KLC1 (Kinesin light chain 1) • STEAP3 (STEAP3 Metalloreductase)
    1m
    A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=100, Recruiting, Cogent Biosciences, Inc.
    New P1 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • NRG1 (Neuregulin 1)
    |
    HER-2 overexpression • HER-2 mutation • NRG1 fusion